studi
investig
hepat
b
viru
hbv
genotyp
resist
profil
nucleo
ide
analogu
na
experienc
chines
patient
chronic
hbv
infect
serum
hbv
dna
extract
revers
transcriptas
region
analys
highsensit
direct
pcr
sequenc
verifi
clonal
sequenc
necessari
drugresist
mutat
detect
patient
includ
patient
receiv
lamivudin
lam
patient
receiv
adefovir
adv
five
patient
receiv
telbivudin
patient
receiv
variou
sequentialcombin
na
therapi
advresist
mutat
detect
patient
receiv
lam
switchedto
adv
contrast
one
patient
receiv
adv
addon
lam
entecavir
etv
resist
mutat
detect
lamand
etvtreat
patient
also
lamtreat
patient
doubl
mutat
detect
frequent
genotyp
c
genotyp
b
viru
patient
infect
mutant
higher
alanin
transaminas
level
infect
mutant
contain
substitut
alon
multidrugresist
hbv
strain
identifi
eight
patient
includ
two
novel
strain
mutat
pattern
result
provid
new
inform
hbv
genotyp
resist
profil
larg
cohort
chines
patient
chronic
hbv
infect
may
import
clinic
implic
hbv
drug
resist
manag
china
hepat
b
viru
hbv
chronic
infect
afflict
million
peopl
worldwid
million
live
china
morbid
mortal
chronic
hepat
b
chb
link
persist
viral
replic
evolut
chbrelat
liver
cirrhosi
chblc
hepatocellular
carcinoma
hcc
china
four
nucleo
ide
analogu
na
ie
lamivudin
lam
adefovir
adv
entecavir
etv
telbivudin
ldt
current
approv
treatment
hbv
infect
whilst
recent
develop
tenofovir
tdf
still
unavail
treatment
chb
chblc
aim
suppress
viral
replic
lowest
possibl
level
therebi
halt
progress
liver
diseas
howev
viral
resist
main
drawback
longterm
antivir
therapi
suboptim
treatment
regimen
drugresist
viral
infect
increas
incid
drug
resist
may
favour
select
multidrugresist
mdr
hbv
resist
mutat
locat
revers
transcriptas
rt
region
hbv
polymeras
gene
classic
lamresist
mutat
often
coexist
compensatori
mutat
two
wellrecogn
advresist
mutat
purport
mutat
may
reduc
suscept
adv
although
still
controversi
substitut
conjunct
lamresist
mutat
result
etv
resist
crossresist
usual
also
exist
ldt
lam
addit
seem
atyp
substitut
associ
lam
adv
select
may
reduc
typic
extent
virolog
breakthrough
genotyp
antivir
resist
design
presenc
uniqu
nucleotid
correspond
deduc
amino
acid
mutat
drug
target
gene
previous
demonstr
associ
antivir
resist
incid
genotyp
resist
relat
viral
factor
host
factor
treatment
characterist
also
affect
method
use
detect
resist
mutat
patient
popul
studi
sever
method
use
type
hbv
genet
drugresist
mutat
individu
advantag
disadvantag
direct
polymeras
chain
reaction
pcr
sequenc
popular
method
owe
abund
inform
provid
howev
also
consid
less
sensit
type
sampl
low
viral
load
iuml
minor
mutant
subpopul
antivir
strategi
becom
avail
treatment
chb
chblc
risk
pattern
resist
crossresist
emerg
divers
nonoptim
strategi
base
sequenti
use
na
increas
develop
mdr
strain
knowledg
incid
pattern
drugresist
mutant
valuabl
clinician
would
assist
clinic
monitor
manag
resist
date
data
larg
deriv
clinic
trial
cohort
limit
drug
resist
profil
studi
intend
investig
populationbas
profil
hbv
genotyp
resist
chines
patient
improv
direct
pcr
sequenc
assay
serum
sampl
collect
chb
chblc
patient
visit
beij
hospit
juli
standard
diagnos
chb
chblc
base
chines
manag
scheme
diagnost
therapi
criteria
viral
hepat
describ
elsewher
malefemal
ratio
averag
age
year
time
sampl
hbv
genotyp
patient
hbsag
posit
patient
hbeag
posit
median
alanin
transaminas
alt
level
ul
median
hbv
dna
level
iuml
patient
receiv
antihbv
na
lam
adv
etv
ldt
monotherapi
combin
sequenti
therapi
minimum
month
written
inform
consent
analysi
obtain
everi
patient
studi
approv
ethic
committe
beij
hospit
biochem
serolog
marker
quantit
hbv
dna
serum
alt
hbsagantihb
hbeagantihb
antihbc
biochem
serolog
marker
well
hbv
dna
level
routin
measur
detect
central
clinic
laboratori
beij
hospit
hbv
dna
level
determin
realtim
quantit
pcr
qpcr
fosun
pharmaceut
co
ltd
shanghai
china
lower
detect
limit
iuml
copiesml
hepat
b
viru
gene
fragment
nt
encompass
complet
rt
gene
amplifi
nest
pcr
sens
antisens
primer
firstround
pcr
cag
gaa
gac
agc
cta
ctc
nt
tga
agc
gaa
gtg
cac
nt
respect
sens
antisens
primer
secondround
pcr
ctg
ctg
gtg
gct
cca
gtt
nt
cgc
agt
atg
gat
cgg
nt
respect
firstround
pcr
consist
cycl
decreas
everi
cycl
cycl
secondround
pcr
conduct
tube
consist
cycl
pcr
product
purifi
use
qiaquick
gel
extract
kit
qiagen
hilden
germani
sequenc
perform
use
abi
dna
analyz
appli
biosystem
foster
citi
ca
usa
sequenc
data
analys
use
vector
nti
suit
softwar
packag
informax
frederick
md
usa
mutat
locat
includ
rt
gene
analys
defin
signatur
lamresist
mutat
lamr
also
encompass
ldtresist
mutat
defin
signatur
advresist
mutat
advr
v
defin
signatur
etvresist
mutat
etvr
concomit
coexist
advr
lamr
etvr
defin
coexistr
repres
coincid
detect
hbv
mutant
resist
nucleosid
nucleotid
analogu
viral
quasispeci
mdr
mutat
identifi
coexistr
sampl
differ
mutat
coloc
clone
viral
sequenc
addit
signatur
mutat
includ
drugresist
mutat
pattern
present
signatur
resist
mutat
ta
clone
pcr
product
purifi
qiaquick
pcr
purif
kit
qiagen
incub
datp
taq
dna
polymeras
purifi
qiaquick
gel
extract
kit
ligat
transform
perform
accord
instruct
pgemt
vector
system
ii
promega
madison
wi
usa
amplicon
purifi
qiaprep
spin
miniprep
kit
qiagen
clone
target
gene
sequenc
primer
six
addit
primer
use
sequenc
fulllength
hbv
genom
hepat
b
viru
genotyp
assign
base
phylogenet
analysi
spgene
sequenc
nt
previous
describ
data
present
mean
sd
median
group
comparison
perform
use
wilcoxon
chisquar
test
use
sa
softwar
sa
institut
inc
cari
nc
usa
p
valu
less
consid
statist
signific
conveni
evalu
sampl
assign
four
group
base
hbv
dna
level
ie
iuml
group
iuml
iuml
group
b
iuml
iuml
group
c
iuml
group
lamresist
mutat
usual
concomit
contrast
often
accompani
resist
mutat
detect
patient
receiv
monotherapi
domin
pattern
lam
andor
domin
pattern
adv
mutat
contain
domin
pattern
ldt
resist
mutat
detect
patient
treat
etv
monotherapi
tabl
hbv
mutat
pattern
patient
treat
sequentialcombin
therapi
divers
amongst
harbour
etvr
mutant
harbour
coexistr
mutant
tabl
significantli
differ
two
group
median
vs
p
tabl
summar
incid
purport
mutat
differ
na
treatment
schedul
includ
alon
pattern
togeth
signatur
resist
mutat
present
tabl
incid
ldt
telbivudin
monoor
sequentialcombin
therapi
last
month
blackwel
publish
ltd
liu
et
al
rel
high
wherea
incid
quit
low
mutat
potenti
resist
tdf
detect
identifi
mdr
mutat
clonal
sequenc
clone
sampl
perform
sampl
identifi
coexistr
direct
pcr
sequenc
result
show
eight
sampl
contain
differ
monodrugresist
mutant
wherea
eight
harbour
mdr
hbv
strain
without
nonmdr
strain
coexist
fig
two
novel
mdr
hbv
strain
tripl
genotyp
resist
lam
adv
etv
identifi
one
sampl
mutat
pattern
two
strain
genbank
access
number
respect
emerg
drugresist
mdr
hbv
strain
close
associ
drug
administr
schedul
clinic
featur
fig
hepat
b
viru
drug
resist
develop
success
genotyp
resist
phenotyp
resist
virolog
breakthrough
biochemicalclin
breakthrough
earli
discoveri
genotyp
resist
allow
time
adjust
therapi
strategi
avoid
virolog
rebound
hepat
flare
distinguish
suboptim
respons
caus
nonvir
factor
satisfi
clinic
requir
need
highsensit
resistancetyp
assay
though
direct
sequenc
wide
use
detect
substitut
taken
consid
rel
lesssensit
assay
develop
highsensit
nest
pcr
assay
allow
us
analys
sampl
quit
low
viral
load
sar
coronaviru
studi
hbv
dna
level
quantit
central
clinic
laboratori
hospit
perform
direct
pcr
sequenc
assay
without
know
viral
load
beforehand
thu
sequenc
success
rate
relat
serum
hbv
dna
level
substanti
object
small
proport
sampl
posit
ie
iuml
hbv
dna
quantit
routin
qpcr
neg
hbv
gene
amplif
direct
sequenc
fact
sampl
group
b
iuml
iuml
sampl
group
c
iuml
iuml
although
lower
detect
limit
latter
assay
set
iuml
calibr
standard
may
attribut
differ
methodolog
eg
direct
pcr
sequenc
assay
need
amplifi
much
longer
viral
gene
fragment
routin
qpcr
thu
influenc
viru
disintegr
similar
phenomenon
lamr
advr
etvr
repres
lamivudin
adefovirand
entecavirresist
mutat
respect
coexistr
repres
coexist
detect
lamretvr
advr
viral
popul
ldt
telbivudin
monoor
sequentialcombin
therapi
last
month
also
observ
investig
although
line
probe
assay
detect
minor
sequenc
low
viru
pool
hbv
dna
concentr
less
iu
ml
requir
onetub
pcr
assay
amplicon
firstround
pcr
subject
secondround
pcr
inhibitori
effect
firstround
pcr
product
elimin
special
techniqu
chines
patent
applic
number
contribut
higher
sensit
assay
advantag
plu
low
cost
permit
use
direct
pcr
sequenc
assay
monitor
drug
resist
clinic
hepat
b
viru
rt
sequenc
avail
nearli
patient
undetect
hbv
dna
routin
qpcr
impli
low
viraemia
may
still
exist
natreat
patient
good
virolog
respons
offer
circumstanti
explan
frequent
rapid
relaps
mani
na
respond
treatment
discontinu
resist
mutat
detect
patient
viral
load
less
iuml
suggest
low
viral
replic
may
reduc
prevent
drug
resist
develop
clinic
practic
hbv
dna
quantit
still
practic
genotyp
resist
test
monitor
drug
resist
patient
good
virolog
respons
consid
costeffect
observ
patient
moder
level
hbv
dna
iuml
higher
resist
mutat
incid
higher
viral
load
one
explan
could
presenc
antivir
agent
suboptim
suppress
viru
replic
may
provid
greater
replic
advantag
mutant
wild
type
poor
suppress
viru
replic
influenc
factor
may
includ
differ
treatment
strategi
durat
coexistr
etvr
repres
entecavirresist
mutat
coexistr
repres
coexist
detect
lamretvr
advr
viral
popul
lam
lamivudin
adv
adefovir
etv
entecavir
ldt
telbivudin
monoor
sequentialcombin
therapi
last
month
vari
advr
pattern
detect
patient
receiv
lam
switchingto
adv
receiv
addon
adv
consist
find
group
interestingli
lamr
pattern
also
detect
frequent
adv
addon
group
one
possibl
reason
adv
rel
weaker
potenc
suppress
lamresist
mutant
whilst
lam
stronger
potenc
suppress
advresist
one
usual
concomit
therefor
lam
switchingto
ldt
unsuit
ymdd
mutat
occur
ldt
ineffect
mutant
though
remain
effect
singl
mutat
preexist
etvr
pattern
detect
lamexperienc
patient
may
account
primari
resist
rapid
failur
etv
treatment
lamrefractori
patient
incid
mutat
pattern
report
significantli
differ
genotyp
b
c
hbv
observ
signific
differ
studi
found
incid
concomit
significantli
higher
genotyp
c
genotyp
b
patient
higher
alt
level
compar
alon
compens
replic
capac
ymdd
mutant
higher
viral
replic
may
induc
stronger
immun
respons
plausibl
elev
alt
associ
fluctuat
cycl
viral
replic
hepat
inflamm
consist
observ
report
decreas
serum
alt
normal
significantli
adv
therapi
sever
nonsignatur
mutat
associ
na
select
amongst
report
compens
loss
replic
effici
associ
acquisit
lam
resist
particularli
case
result
consist
view
concur
occur
proport
equal
presenc
absenc
compensatori
mutat
occur
frequent
genotyp
c
genotyp
b
vs
p
common
lamandor
advtreat
patient
contrast
like
concomit
mutat
lower
incid
associ
purport
mutat
drug
resist
need
clarif
multidrugresist
strain
often
aris
suboptim
sequenti
combin
therapeut
strategi
result
rapid
complet
viral
suppress
especi
larg
replic
space
avail
mutant
spread
nevertheless
nucleosid
lam
etv
ldt
nucleotid
analogu
adv
usual
complementari
crossresist
profil
use
combin
mdr
hbv
strain
usual
incid
number
mutat
indic
bracket
lam
lamivudin
adv
adefovir
etv
entecavir
ldt
telbivudin
na
nucleo
ide
analogu
monoor
sequentialcombin
therapi
last
month
chang
serum
hbv
dna
alt
level
present
along
success
antivir
therapi
dynam
chang
wildtyperesist
mutant
analys
clonal
sequenc
clone
sampl
depict
pie
chart
serial
red
dash
repres
lower
detect
limit
hbv
dna
clinic
iuml
blue
dash
repres
upper
normal
limit
alt
ul
lam
lamivudin
adv
adefovir
etv
entecavir
ifn
interferon
alt
alanin
transaminas
hbv
hepat
b
viru
drug
comparison
wildtyp
stain
unlik
rigor
design
clinic
trial
patient
enrol
studi
follow
varieti
na
schedul
treatment
durat
vari
extens
durat
treatment
might
influenc
incid
resist
hbv
strain
although
influenc
rel
minor
larg
popul
sampl
studi
mani
patient
receiv
differ
na
therapi
came
seek
medic
care
hospit
sampl
baselin
earli
stage
treatment
unavail
make
investig
hard
systemat
howev
present
populationbas
crosssect
investig
advantag
acquir
overal
hbv
resist
profil
clinic
practic
make
greatli
inform
taken
togeth
result
provid
new
insight
hbv
genotyp
resist
profil
larg
cohort
chines
patient
chronic
hbv
infect
may
import
clinic
implic
manag
hbv
drug
resist
china
